Home » John Crison

John Crison

Sep 28, 2007
Premium
John Crison has Joined Simulations Plus as its director of life sciences.
The company, which offers simulation and modeling software for pharmaceutical discovery and development, announced that Crison replaces Michael Bolger, who has “served the company very well” for 11 years.
 
However, Bolger moved 350 miles from company offices in Lancaster, which was no longer in line with company needs.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

NIH's Collins on Harassment

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

With Eight Arms and Giant Eyes

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Missing From Trials

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

This Week in Cell

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.

Oct
02
Featured Webinar

Utilization of Multiple Molecular Testing Methodologies to Aid in Lung Cancer Patient Management

Sponsored by
Roche

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.  

Oct
11
Featured Webinar

Validation of Error-Corrected Sequencing for Hematological Malignancies

Sponsored by
ArcherDX

This webinar will discuss a validation study for a next-generation sequencing (NGS) assay for hematological malignancies (e.g., acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms).

Nov
05
Featured Webinar

Overcoming Challenges in Solid Tumor Testing with Advanced AI

Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

What's Popular?

In Informatics

  1. Golden Helix Gets $1.8M to Improve Detection Algorithms for Complex Variants in NGS Data

    Premium

  2. Congenica to Tailor Sapienta Genome Analysis Platform for Chinese Market

  3. Vertebrate Genomes Project Releases First Assemblies; Describes Challenges, Plans

    Premium

  4. Roche Introduces Clinical Trial Matching Feature in Navify Tumor Board Solution

    Premium

  5. Repositive to Launch Personalized Cancer Model Matching Service

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.